NON CLEAR CELL RCC IN SORAFENIB EAP (NA ARCCS)
‐
‐
Best Response Rates by Patient Subgroup
*
, %
Treatment
naïve
Previously
treated
NCC,
Papillary
NCC,
Chromophobe
Brain
metastases
Prior
bevacizumab use
Elderly
(n = 537)
(n = 951)
(n = 940)
(n = 107)
(n = 20)
(n = 50)
(n = 99)
CR
1 (<1)
0
0
0
0
0
0
PR
38 (4)
29 (3)
3 (3)
1 (5)
2 (4)
5(3)
19 (4)
SD ≥ 8 wks
752 (79)
759 (81)
87 (81)
17 (85)
34 (68)
154 (77)
427 (80)
PD
160 (17)
152 (16)
17 (16)
2 (10)
14 (28)
40 (20)
91 (17)
CR + PR + SD
791 (83)
788 (84)
90 (84)
18 (90)
36 (72)
159 (80)
446 (83)
NCC, non-clear cell; CR, complete response.
68
*Includes patients valid for radiologic response assessments and subjects valid for clinical and radiologic response assessment.
Stadler WM, et al. Cancer 2010;116:1272‐80
